Related Party Transactions - Textual (Details) (USD $)
|
1 Months Ended | 1 Months Ended | 0 Months Ended | 1 Months Ended | 1 Months Ended | 0 Months Ended | 1 Months Ended | 0 Months Ended | 1 Months Ended | 3 Months Ended | 1 Months Ended | 1 Months Ended | 1 Months Ended | 1 Months Ended | 3 Months Ended | 0 Months Ended | 1 Months Ended | ||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jan. 30, 2013
Notes [Member]
Notes Due February 1, 2033 [Member]
|
Sep. 30, 2009
Convertible Preferred Stock [Member]
|
Oct. 31, 2013
Zebra [Member]
|
Oct. 31, 2013
Zebra [Member]
Series A Preferred Stock [Member]
|
Oct. 31, 2013
Zebra [Member]
Restricted Stock [Member]
|
Feb. 29, 2012
Chromadex Corporation [Member]
|
Feb. 29, 2012
Biozone Pharmaceuticals Inc [Member]
|
Nov. 30, 2010
Fabrus Inc [Member]
|
Sep. 21, 2009
Cocrystal [Member]
|
Sep. 30, 2009
Cocrystal [Member]
|
Aug. 31, 2011
Dr Frost [Member]
|
Aug. 29, 2013
Dr Frost [Member]
OPKO Biologics [Member]
|
Oct. 31, 2013
Dr Frost [Member]
Zebra [Member]
Series A Preferred Stock [Member]
|
Aug. 31, 2011
Dr. Hsiao [Member]
|
Oct. 31, 2013
Equity Method Investee [Member]
|
Oct. 31, 2013
Equity Method Investee [Member]
ARNO [Member]
|
Oct. 31, 2013
Equity Method Investee [Member]
ARNO [Member]
One Year Warrants [Member]
|
Oct. 31, 2013
Equity Method Investee [Member]
ARNO [Member]
Five Year Warrants [Member]
|
Dec. 31, 2013
Equity Method Investee [Member]
Sorrento [Member]
|
Jun. 30, 2009
Equity Method Investee [Member]
Sorrento [Member]
|
Jan. 16, 2014
Equity Method Investee [Member]
Biozone [Member]
|
Jan. 03, 2014
Equity Method Investee [Member]
Biozone [Member]
|
Dec. 31, 2013
Equity Method Investee [Member]
Biozone [Member]
|
Jul. 31, 2012
Equity Method Investee [Member]
Biozone [Member]
|
Jan. 03, 2014
Equity Method Investee [Member]
Biozone [Member]
Series B Convertible Preferred Stock [Member]
|
Jan. 03, 2014
Equity Method Investee [Member]
MusclePharm Corporation [Member]
Common Stock [Member]
|
Aug. 31, 2011
Mr. Rubin [Member]
|
Aug. 29, 2013
Mr. Rubin [Member]
OPKO Biologics [Member]
|
Sep. 21, 2011
Mr. Rubin [Member]
Biozone Pharmaceuticals Inc [Member]
|
Jan. 30, 2013
Frost Gamma Investments Trust and Hsu Gamma Investment, L.P. [Member]
Notes [Member]
Notes Due February 1, 2033 [Member]
|
Dec. 31, 2012
Avi Properties LLC [Member]
sqft
|
Mar. 31, 2014
Teva [Member]
FineTech [Member]
|
Feb. 29, 2012
Scripps Research Institute [Member]
|
Feb. 29, 2012
Gamma Trust [Member]
Chromadex Corporation [Member]
|
Feb. 29, 2012
Hsu Gamma [Member]
Chromadex Corporation [Member]
|
Nov. 30, 2010
Dr. Lerner [Member]
Fabrus Inc [Member]
|
Nov. 30, 2010
Gamma Trust and Hsu Gamma [Member]
Fabrus Inc [Member]
|
Jun. 30, 2010
Academia Sinica [Member]
|
Sep. 30, 2009
Frost Group, LLC [Member]
Installment
|
Aug. 31, 2012
Real Estate Holdings LLC [Member]
|
Nov. 30, 2007
Real Estate Holdings LLC [Member]
sqft
|
Jan. 02, 2014
Real Estate Holdings LLC [Member]
sqft
|
Oct. 31, 2013
FTC Filings [Member]
Dr. Hsiao [Member]
|
Mar. 31, 2014
Reimbursement Of Travel Expense [Member]
Dr Frost [Member]
|
Mar. 31, 2013
Reimbursement Of Travel Expense [Member]
Dr Frost [Member]
|
May 02, 2013
Lab Space Agreement [Member]
Dr. Hsiao [Member]
sqft
|
May 02, 2013
Consulting Agreement [Member]
Dr. Hsiao [Member]
|
Oct. 31, 2013
Loans Receivable [Member]
Fabrus [Member]
|
Dec. 31, 2013
License Agreement Early Termination Fee [Member]
Equity Method Investee [Member]
Sorrento [Member]
|
|
Related Party Transaction [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||
Payments for Filing Fees | $ 170,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Invested in common shares | 2,000,000 | 2,500,000 | 2,500,000 | 2,000,000 | 2,300,000 | 500,000 | |||||||||||||||||||||||||||||||||||||||||||
Private Placement Financing | 30,000,000 | 2,750,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Investment Owned, Balance, Shares | 840,000 | 900,000 | 833,333 | 1,000,000 | |||||||||||||||||||||||||||||||||||||||||||||
Warrants expiration period | 1 year | 5 years | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants to purchase common shares | 8,500,000.0 | 833,333 | 833,333 | 1,000,000 | |||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | 2.40 | 4.00 | 0.50 | ||||||||||||||||||||||||||||||||||||||||||||||
Investment Agreement, Requirement to Hold Rights to Board, Minimum Stock Percentage | 3.00% | ||||||||||||||||||||||||||||||||||||||||||||||||
Equity Method Investment, Ownership Percentage | 23.50% | ||||||||||||||||||||||||||||||||||||||||||||||||
Shares Received As Gift | 900,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Area of Real Estate Property | 11,000 | 5,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Lessor Leasing Arrangements, Operating Leases, Term of Contract | 5 years | ||||||||||||||||||||||||||||||||||||||||||||||||
Contractual Obligation, Due in Fifth Year | 60,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Beneficially owned held by members | 13.00% | 36.00% | 5.00% | 6.00% | 1.00% | 5.00% | 1.00% | 16.00% | 1.00% | ||||||||||||||||||||||||||||||||||||||||
Debt face amount | 175,000,000.0 | 175,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Period of lease | 5 years | ||||||||||||||||||||||||||||||||||||||||||||||||
Square feet of laboratory | 44,000 | 8,300 | |||||||||||||||||||||||||||||||||||||||||||||||
Payments of lease per month | 18,000 | 18,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Exceeds consumer price index | 5.00% | ||||||||||||||||||||||||||||||||||||||||||||||||
Sale of API to TEVA | 100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Fund for research agreement | 900,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Research agreement maturity period | 5 years | ||||||||||||||||||||||||||||||||||||||||||||||||
Approximate funding for development of technology | 200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Period for development of technology | 3 years | ||||||||||||||||||||||||||||||||||||||||||||||||
Invested in common shares | 1,000,000 | 1,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Beneficially owned held by owners | 1.50% | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible senior notes interest rate | 10.00% | ||||||||||||||||||||||||||||||||||||||||||||||||
Par value | $ 0.20 | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants duration | 10 years | 10 years | |||||||||||||||||||||||||||||||||||||||||||||||
Exercise price per share | $ 0.40 | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible debt, stock issued from conversion | 10,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Biozone Pharmaceuticals Warrants Exercised | 7,700,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Noncash or Part Noncash Divestiture, Shares Received | 1,200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued | 1,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Stock Conversion, Common Shares Issued upon Conversion | 205.08308640 | ||||||||||||||||||||||||||||||||||||||||||||||||
Investment was part of financing for Fabrus | 2,100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Ownership percentage held by director | 5.00% | ||||||||||||||||||||||||||||||||||||||||||||||||
Increase (Decrease) in Due from Related Parties | 100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Related Party Transaction, Rate | 7.00% | ||||||||||||||||||||||||||||||||||||||||||||||||
Research and development agreement amount | 200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Equity method investment, number of shares purchased | 1,701,723 | ||||||||||||||||||||||||||||||||||||||||||||||||
Previous investment by a group of investor | 5,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Additional investment by a group of investor | 5,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Number of equal installments payable for additional investment | 2 | ||||||||||||||||||||||||||||||||||||||||||||||||
Equity Method Investment, Realized Gain (Loss) on Disposal | 17,200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Related Party Transaction, Other Revenues from Transactions with Related Party | 2,700,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Lease rent per month for fifth year | 24,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Credit for tenant improvements | 30,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Period of lease agreement | 6 months | ||||||||||||||||||||||||||||||||||||||||||||||||
Operating Leases, Monthly Payments, Year One | 30,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Operating Leases, Monthly Payments, Year Five | 34,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Tenant Improvements, Offset Against Operating Lease in Next Twelve Months | 155,200 | ||||||||||||||||||||||||||||||||||||||||||||||||
Tenant Improvements, Rent Reduction, Amount | 68,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Reimbursement paid to related party for travel | $ 13,000 | $ 13,000 |